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Background: The American Diabetes Association (ADA) has published several diabetes treatment algorithms, but
none have been tested in real-life settings. The aim of this study is to analyze the feasibility of achieving and/or
maintaining HbA1c levels <7.0% using current diabetes treatment guidelines and the resources available in the
public health care system of Brazil.
Methods: A one-year, single-arm interventional study was conducted with type 2 diabetes patients in a primary
care unit. Intervention consisted of intensification of lifestyle changes and sequential prescription of drugs based on
ADA guidelines using the medications available through the publicly funded Unified Health System (Sistema Único
de Saúde, SUS).
Results: Ninety patients (age: 62.7±10.4 years; diabetes duration: 8.2±9.1 years) completed the trial. During the
intervention period, increases were observed in number of oral antidiabetic agent (OAD) classes per patient
(1.50±0.74 vs. 1.67±0.7; p=0.015), OAD pills per patient (2.64±1.89 vs. 3.33±2.23 pills/patient; p <0.001), insulin
dosage (0.20±0.29 vs.0.50±0.36 UI/kg/day; p=0.008) and number of patients on insulin (19 [21%] vs. 31 [34%];
p<0.01), but no improvement in HbA1c (7.2±1.6% vs. 7.3±1.5%; p=0.453) or frequency of patients on target, defined
as HbA1c <7% (53.3% vs. 48.9%; p=0.655). Patients with baseline HbA1c <7% had a small increase in HbA1c during
the trial (6.3±0.4 vs. 6.7±0.9%; p=0.002). No such change was observed in those with baseline HbA1c ≥7%.
Conclusions: In this group of patients with a mean baseline HbA1c of 7.2%, implementation of 2006/2009
ADA/EASD guidelines led to achievement of the therapeutic goal of HbA1c <7% in a small proportion of patients.
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Both the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD)
have published algorithms for management of hypergly-
cemia in patients with type 2 diabetes [1,2]. According
to these algorithms, the first step of diabetes treatment
should consist of lifestyle intervention plus metformin.
If optimal glycemic control is not achieved, step two
consists of addition of either a sulphonylurea or basal in-
sulin. These recommendations have not, however, been
tested in real-life settings. In Brazil, most patients with
type 2 diabetes are treated at primary care clinics and* Correspondence: jorgeluizgross@gmail.com
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reproduction in any medium, provided the orhave access to metformin, sulfonylureas, and NPH insu-
lin, which are provided free of charge by the public
health care system, the Unified Health System (Sistema
Único de Saúde, SUS). Therefore, the aim of this study
was to analyze whether an HbA1c level of <7.0% can be
achieved and maintained in patients with type 2 diabetes
treated at a primary care clinic in accordance with ADA/
EASD guidelines.
Research design and methods
Study design and setting
This one-year, open-label, uncontrolled, single-arm inter-
ventional study was conducted at a primary care clinic
located in the metropolitan area of the city of Porto
Alegre. This clinic is managed by Hospital de Clínicas
de Porto Alegre, a university hospital and reference center,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The study protocol was approved by the Hospital de
Clínicas de Porto Alegre Research Ethics Committee and
registered in the Clinical Trial Protocol Registration Sys-
tem (ID 06260). All patients provided written informed
consent.
Patients
Consecutive adult (age >18 years) patients with type 2
diabetes who attended the primary care clinic regularly
during the 6 months preceding the screening visit were
invited to take part in the study. The exclusion cri-
teria were: history of active infection (e.g. osteomyelitis,
pulmonary tuberculosis, AIDS); chronic corticosteroid
use; unstable angina or myocardial infarction in the last
3 months; advanced renal disease (requiring renal replace-
ment therapy); heart failure (New York Heart Association
class III and IV); cirrhosis; alcohol or illicit drug use;
dementia; current pregnancy or lactation; and current
cancer or any disease that might affect survival during
the next 5 years.
Baseline evaluation
At baseline, patients underwent an evaluation consisting
of a standard history and physical examination. Patients
were classified as current smokers or nonsmokers. Ethni-
city was self-reported as white or nonwhite. Past medical
history was evaluated clinically. Microalbuminuria was
defined by an albumin level >17 mg/L on a random spot
urine sample [3]. Cerebrovascular disease was defined by
the presence of a history of stroke and/or findings con-
sistent with sequelae of stroke. Heart disease was defined
by a history of myocardial infarction, angina or heart fail-
ure and, when available, diagnosed directly by myocardial
perfusion scintigraphy and coronary angiography. Body
mass index (BMI) was calculated using the formula
[weight (kg)/height2 (m)].
Blood pressure was measured twice during each visit,
with patients in the sitting position and after a 10-minute
rest, with an OMRON HEM-720 Automatic Blood Pres-
sure Monitor. Hypertension was defined as blood pressure
levels ≥140/90 mmHg or use of antihypertensive drugs.
Interventions
The study comprised 3 stages: a run-in period (3 months),
the drug intervention period (6 months) and the sta-
bilization period (2-3 months), and was conducted by
an endocrinologist (LVV) and a generalist nurse (MFG).
Eligible patients underwent an interview, clinical exam-
ination and laboratory workup (glucose, HbA1c [HPLC],
lipid profile, liver function tests, creatinine and spot urine
albumin). Lifestyle modification advice was provided in a1-hour appointment during the first study visit, and a
folder containing a diet plan and recommendation of at
least 150 minutes of physical exercise per week was
given to each patient. During the run-in period, patients
received a glucose monitoring device and test strips and
given guidance on how to use the device and record
measurement results. Patients were asked to carry out
fasting blood glucose monitoring (before breakfast), but
only three times per week due to economic constraints.
Patients returned to the primary care clinic for monthly
follow-up and reminders of dietary guidance and the im-
portance of exercise and adherence to current medica-
tions. During the intervention period, participants visited
the clinic once monthly for weight and blood pressure
checks and review of the results of self-monitoring of
blood glucose (SMBG). The goal was to achieve fasting
capillary blood glucose levels (as measured by SMBG) in
the range of 90 to 130 mg/dL. If mean SMGB values were
higher than 130 mg/dL, medications were added in the
following sequence: metformin; glibenclamide; and NPH
insulin, initially at bedtime and, if goals were still not met,
before breakfast as well, according to the 2006 Diabetes
Treatment Algorithm [1]. Medications were started at the
lowest manufacturer-recommended dose and doses were
increased to the maximum tolerated level at monthly
intervals, as guided by SMBG. Another class of glucose-
lowering medication was added after the maximum dose
was reached. HbA1c was measured every 3 to 4 months
for further adjustment of diabetes medications. The last
2–3 months of the study (stabilization period) were used
to observe whether participants’ HbA1c levels had stabi-
lized after the treatment modifications performed during
the intervention period. Throughout the study period,
patients received standard medical care at the primary
care clinic for any adverse events or other concomitant
illnesses.
The study endpoints were change in HbA1c after the
intervention and the proportion of patients achieving
and/or maintaining an HbA1c of < 7% during 1-year
follow-up.
Statistical analysis
Results are expressed as mean ± SD, median (interquartile
range) or N (%). Student’s t test, the Mann-Whitney U test
or chi-square test were used for comparisons. Multivariate
logistical analyses were performed to determine which
factors were associated with HbA1c >7% (dependent
variable). Independent variables were selected on the
basis of their significance on univariate analyses and/or
biological relevance. Sample size was calculated consider-
ing a 0.5% reduction in HbA1c with 1.5% SD. P values
<0.05 (two-sided) were considered statistically significant.
All analyses were performed in SPSS 15.0 (Chicago,
IL, USA).
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A total of 116 patients agreed to take part in the study,
but 26 did not complete the trial: 3 withdrew consent,
16 were lost to follow-up, 2 died, 1 suffered a stroke with
significant sequelae, and 4 developed cancer. These par-
ticipants did not differ from those who completed the
trial in terms of age, duration of diabetes, gender dis-
tribution, ethnicity, or baseline HbA1c. Ninety patients
(age: 62.7±10.4 years, women: 57.8%, whites: 78.9%,
diabetes duration: 8.2±9.1 years, BMI: 29.8±4.9 kg/m2,
systolic blood pressure: 144.3±22.7 mmHg) completed
the trial (Table 1).
At enrollment, 10 (11%) patients were treated with
dietary measures alone, 30 (33%) with metformin alone,Table 1 Baseline clinical and laboratory characteristics of
type 2 diabetic patients included in the study
Baseline
N 90
Age (years) 62.7 ± 10.4
White ethnicity 71 (78.9%)
Women 52 (57.8%)
Diabetes duration (years) 8.2 ± 9.1
Primary care unit attendance (years) 2.1 ± 2.5
Previous cardiovascular event 21 (23.3%)
Current Smoking 13 (14.4%)
Hypertension 79 (89.8%)
SBP (mmHg) 144.3 ± 22.7
DBP (mmHg) 79.4 ± 10.7
BMI (kg/m2) 29.8 ± 4.9
Using statin 45 (50%)
Using aspirin 55 (61.1%)
Microalbuminuria 20 (23.8%)
Treatment Type
Diet only 10 (11.1%)
One oral agent 33 (36.6%)
Metformin 30
Glybenclamide 3
Two oral agents 28 (31.1%)
Insulin use 19 (21.1%)
NPH alone 4
NPH + Metformin 14
NPH + Glybenclamide 0
NPH + Metformin + Glybenclamide 1
Total cholesterol (mg/dl) 179.1 ± 41.2
HDL cholesterol (mg/dl) 47.5 ± 11.8
Triglycerides (mg/dl) 153 (109.0 -216.5)
LDL cholesterol (mg/dl) 94.9 ± 33.0
Creatinine (mg/dl) 0.86± 0.24
HbA1c (%) 7.2 ± 1.6
Data are mean ± SD, number of patients with the characteristic (%).3 (3%) with a sulphonylurea alone, 28 (31%) with met-
formin and a sulphonylurea combined, and 19 (21%)
were on insulin (4 on insulin alone). During the inter-
vention period, the number of oral agents employed rose
(1.50±0.74 vs. 1.67±0.7; p=0.015), as did the pill burden
(2.64±1.89 vs. 3.33±2.23 pills/patient; p <0.001). Several
patients started insulin therapy, increasing the number
of patients on insulin from 19 (21%) to 31 (34%) (p <0.01).
There was also a significant increase in mean insulin
dosage (0.20±0.29 vs.0.50±0.36 UI/kg/day; p=0.008) in
patients who had been on insulin since baseline; despite
this increase, no episodes of severe hypoglycemia were
reported. At baseline, mean HbA1c was 7.2±1.6%, and
no change was observed during the follow-up period
(7.30±1.48%; p=0.453; Figure 1A). The number of patients
with HbA1c within target values was 48 (53.3%) at base-
line and 44 (48.9%) at the end of the study (p=0.655). No
individual factor could predict final HbA1c ≥7%, except
for age at diabetes onset (OR: 0.963; 95%CI 0.930–0.997;
p=0.033) and insulin use at baseline (OR: 3.412; 95%CI
1.110–10.491; p=0.032).
Based on the mean of two initial HbA1c measurements
(baseline and end of run-in), patients were divided into
two groups: HbA1c <7% (n=55, 61%) and HbA1c ≥7%
(n=35, 39%). No between-group differences in age, gender,
diabetes duration, and BMI were detected. Patients with
HbA1c <7% had a significant increase in HbA1c (6.30±0.43
vs. 6.71±0.90%; p=0.002) during the study period, while
those with HbA1c ≥7% did not experience such changes
(8.6±1.5% vs. 8.3±1.7%; p=0.64) (Figure 1B). At the end
of the study, 39 (71%) of 55 patients still has HbA1c levels
<7%, whereas only 7 (20%) of 35 patients in the baseline
HbA1c ≥7% group reached this goal.
Conclusions
In this sample of patients with type 2 diabetes attending a
primary care clinic, recommendation of lifestyle modifica-
tions and intensification of treatment with traditional anti-
hyperglycemic agents were not enough to decrease HbA1c
to (or or maintain A1c at) ADA/EASD goals. It is widely
recognized that most antidiabetic treatments fail as mono-
therapy as time goes by [4,5], and that administration of
additional antihyperglycemic agents, including insulin,
enables achievement of HbA1c goals in approximately
50% of patients [6,7]. In our study, only 16% of patients
reached the target of HbA1c <7%, increases in dosage and
number of antihyperglycemic agents notwithstanding.
It should be noted that this cohort of patients was
relatively well controlled (mean HbA1c 7.2%; 6.1–7.9%),
which is far below the expected for DM patients in Brazil.
In Brazil, the prevalence of inadequate metabolic control
(defined as HbA1c >7%) in the diabetic population is
76% [8], and in the latest countrywide diabetes surveil-
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Figure 1 HbA1c values during the study: Panel A – General view of the HbA1c in the 90 patients and medication prescribed during
the study. Panel B – HbA1c ≥7% and HbA1c <7% behavior throughout the study.
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study requires caution, as it was conducted at a primary
care clinic run by a university hospital. Nevertheless, it
shows that good glycemic control can be achieved with
the resources available in the public health care system
through application of international clinical guidelines.
Baseline HbA1c might be a determinant of glycemic
response to antidiabetic therapies [10,11], and a small
reduction in HbA1c could be expected in this sample.
Even so, a small increase in HbA1c in patients with
HbA1c <7% was observed, whereas no improvement was
found in those with higher HbA1c levels at baseline.
Since diabetes is a progressive disease, stability of HbA1clevels during the study period can also be considered a
partial success.
Limitations of this study include the absence of a con-
trol group and the small sample size. In a French study
of similarly standardized diabetes care, no improvement
in A1c was observed in the interventional group over the
course of the trial (7.5±1.8 vs. 7.2±1.5; p=0.1), but deteri-
oration occurred in the control group, resulting in a
between-group difference of -0.87% at the end of the trial
[12]. Recently, the ADA and EASD published a new
patient-centered strategy for management of diabetes.
This new protocol still uses the same principles applied
in this study, but is less centered on HbA1c targets [13].
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of HbA1c goals seems reasonable, and less strict glycemic
control may be achievable with the medications available
in the Brazilian Unified Health System.
In conclusion, implementation of the ADA/EASD
2006/2009 guidelines led to achievement of HbA1c <7%
in a small proportion of patients with type 2 diabetes. It
bears noting that the included patients had good meta-
bolic control—far beyond that of the general Brazilian dia-
betic population—at baseline. In this group of patients,
review of anti-hyperglycemic management strategies, per-
haps employing a more aggressive lifestyle intensification
strategy [16] and/or including new classes of antidiabetic
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